Obstetrics & Neonatal Research
Research is one of the components that make us unique at Baptist Health Lexington. Our highly trained staff is dedicated to providing the latest innovations and newest therapies in a community-based setting. Baptist Health Lexington is working to improve the lives of our obstetrics patients.
No neonatal clinical trials at this time.
Below is a listing of current obstetric clinical trials:
IRB 1034-Actim Partus Test Study:
Study Title: Clinical Evaluation of the Actim Partus Test. Clinical Protocol Number: 1004201
Purpose: to evaluate the ability of an investigational test to predict the risk of preterm or imminent delivery using cervical samples collected with a sterile swab in women less than 36 weeks pregnant and presenting with signs and/or symptoms suggestive of preterm labor and whose fetal membranes are not ruptured.
This research study is being sponsored by Alere Scarborough, Inc.
Primary eligibility: Pregnant women between gestational age week 21+6 and week 35+6, presenting for unplanned obstetrical care with signs/symptoms suggestive of preterm labor.
For additional information, please contact Ruthie Hoefner at 859.260.4527 or Karen Willis at 859.260.6440
IRB 1027-RLX030/Serelaxin Study (preeclampsia study):
Study Title: An adaptive multicenter, randomized, partially double-blind, placebo-controlled study to assess the safety, PK and PD/efficacy of RLX030 in women with pre-eclampsia. Protocol Number: CRLX030A2205
Purpose: to determine if Serelaxin (RLX030) is safe, well tolerated, and effective in the treatment of preeclampsia.
This research is funded by the pharmaceutical company named Novartis
- Serelaxin is a protein made in the laboratory (“man made”) that mimics (or acts like) the naturally occurring Relaxin hormone. The naturally occurring Relaxin hormone circulates in the blood streams. Based on the important role Relaxin plays in pregnancy, in which it causes the blood vessels to dilate and help’s mom’s body to adapt to the increasing demands of the baby during pregnancy, this hormone is a candidate for the treatment of preeclampsia.
Primary eligibility: Women at 18 to 40 years of age who have been diagnosed with preeclampsia and are 28 to 33 weeks pregnant requiring hospitalization.
For additional information, please contact Karen Willis at 859.260.6440 or Ruthie Hoefner at 859.260.4527.